Adenocarcinoma, Carcinoma NOS, Melanoma, Neuroendocrine Tumors
Conditions
Keywords
Gene Therapy, Follow-Up, Delayed Toxicity, Natural History, Adenocarcinoma, Melanoma, Neuroendocrine Tumors, Carcinoma
Brief summary
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA. Eligibility: Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol Design Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
Detailed description
Background: * Patients receiving care at the NIH Clinical Center are required to be enrolled on a clinical protocol. * Following participation in a treatment protocol, it may be in the best interest of the patient to continue to be followed at the Clinical Center. * The National Cancer Institute Surgery Branch (NCI-SB) conducts clinical trials utilizing gene transfer. The current U.S. Food and Drug Administration (FDA) requirements for long-term follow-up are up to fifteen years for some products. As this time-period is frequently longer than studies are expected to be open, a long-term follow-up protocol is necessary to ensure the follow-up of these participants. Objective: -Primary objective: --Provide a mechanism for long-term follow-up of participants who have participated in research studies in the NCI-SB. Eligibility: * Age greater than or equal to 18 years. * Participant has been enrolled on an NCI-SB treatment protocol. Design: * Participant will undergo physical exams, laboratory evaluation, imaging, or phone follow-up as clinically indicated. * Procedures that entail more than minimal risk to the patient should not be performed for research purposes on this protocol.
Interventions
None listed
Sponsors
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: * Age greater than or equal to 18 years. * Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study). * For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
Exclusion criteria
-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long-term follow-up | Until time of death | Long-term follow-up of subjects who have participated in research studies in the NCI Surgery Branch |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Long-term follow-up for gene therapy studies | 15 years | Collection of long-term, follow-up information on subjects who have participated in gene transfer studies as required by the FDA and other regulatory groups |
| Survival | Until time of death | Follow subjects who have participated in research studies in the NCI Surgery Branch until time of death |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSteven A Rosenberg, M.D.
National Cancer Institute (NCI)
Outcome results
None listed